If your cat is fat, there’s finally something genuinely new to talk about. Not a prescription diet that requires military-grade portion discipline. Not a puzzle feeder. An actual drug, working the same biological pathway as Ozempic and Wegovy, designed specifically for your overweight pet.

Two companies are moving fast. Akston Biosciences presented data on AKS-562c, a weekly injectable GLP-1 therapy for cats, at the ACVIM Forum in Seattle on June 11-13, 2026. Twelve weeks of treatment. No treatment-related toxicity. Reduced food intake. That’s not a dramatic result, but in early-phase pharmaceutical research, “safe and it does the thing” is exactly what you need. Separately, OKAVA Pharmaceuticals has already launched MEOW-1, the first-ever GLP-1 clinical trial in cats or dogs, enrolling at least 50 overweight cats for a six-month subcutaneous implant called OKV-119. Results are expected mid-2026. This is happening now, not in some theoretical future.

Here’s why that matters: 61% of cats and 59% of dogs in the U.S. were classified as overweight or obese as of 2022, according to the Association for Pet Obesity Prevention. We have not moved the needle meaningfully on those numbers in years. Diet counseling and feeding guidelines work beautifully in theory and collapse in practice the moment a cat figures out how to stare at you with genuine moral authority at 4 a.m.

What GLP-1 Drugs Actually Do (and Why Cats Are First)

GLP-1 stands for glucagon-like peptide-1. In humans, drugs like semaglutide mimic this hormone to slow gastric emptying, increase feelings of fullness, and reduce appetite. The result is that people eat less without fighting the urge to eat more. The mechanism doesn’t care if you’re human or feline, which is why researchers made the leap.

Cats got the first trial partly because feline obesity carries particularly nasty metabolic consequences, including hepatic lipidosis, a life-threatening liver condition that can develop shockingly fast when an obese cat stops eating for almost any reason. Cats are also physiologically interesting test subjects for metabolic research, though I’ll spare you the biochemistry. The practical point: if the feline data holds, OKAVA and Akston researchers have both indicated a dog-specific GLP-1 trial is planned as a follow-on.

The delivery method for OKV-119 is worth noting. It’s a subcutaneous implant, not a daily pill or a shot you administer at home. That removes the biggest compliance problem in veterinary medicine: owner-administered medication. Anyone who has tried to give a cat a pill twice daily for 30 days understands why “a six-month implant your vet places once” is a genuinely compelling design choice.

What These Drugs Are Not (Yet)

Recommended Vet-Approved Dog First Aid Kit with Tick Remover

Essential pet emergency kit with first aid guide, slip leash, and medical supplies for home, car, and camping.

Check Price →

Helpful resource: Purina Pro Plan Veterinary Supplements FortiFlora Probiotic is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)

Pump the brakes before you call your vet asking for a GLP-1 prescription. These drugs are not FDA-approved. They are not commercially available. Every cat currently receiving them is enrolled in a controlled clinical trial, and that’s the only legal avenue right now. There is no compounded version of AKS-562c your vet can order. OKV-119 is not at your local veterinary pharmacy.

The reason I’m spelling this out: human GLP-1 drugs are already being requested for pets by owners who’ve read half an article. Semaglutide and tirzepatide are dosed by body weight for humans who weigh 150 to 300 pounds. The math does not translate cleanly to a 15-pound cat, and the safety profile in cats is entirely unknown. Do not try this. Seriously. The fact that something works in one species at one dose tells you almost nothing about what it does in a different species at a scaled dose.

What you can do right now is check whether your cat qualifies for MEOW-1 enrollment. The trial is actively recruiting overweight cats, and participation typically means access to the drug at no cost, regular veterinary monitoring, and contributing real data to research that could benefit millions of animals. Ask your vet, or look up OKAVA Pharmaceuticals directly.

How to Have a Useful Conversation With Your Vet About This

Most vets at this moment are fielding questions from clients who’ve seen a headline and want a quick answer. Help your vet help you by being specific. Don’t walk in asking “what do you think about Ozempic for cats?” Walk in asking about AKS-562c and MEOW-1 by name, and whether your cat’s current weight and health status would make them a reasonable candidate for trial enrollment.

Your vet will want to assess body condition score, rule out underlying causes of weight gain like hypothyroidism or other endocrine disorders, and discuss whether your cat has any conditions that might affect trial eligibility. Cats with certain comorbidities may not qualify.

If your vet hasn’t heard about the ACVIM Forum presentations yet, that’s genuinely fine. The data dropped in mid-June 2026. Share the dvm360 coverage from June 17, 2026 and let them read it. Good vets appreciate clients who show up with actual sources rather than secondhand panic.

In the meantime, weight management still means what it’s always meant: measured meals, appropriate caloric targets, limiting treats to under 10% of daily calories, and ideally some form of food puzzle or activity enrichment to slow intake. These aren’t exciting. They work imperfectly. But they’re what exists commercially right now, and they’re worth doing rather than waiting for a drug that isn’t yet available.

The Bigger Picture: Veterinary Metabolic Medicine Is Moving

Drug/TrialSpeciesDeveloperDelivery MethodTimelineStatus
AKS-562cCatsAkston BiosciencesWeekly injectable12 weeks treatmentData presented June 2026
OKV-119CatsOKAVA PharmaceuticalsSubcutaneous implant6 monthsMEOW-1 trial, results expected mid-2026
Pimobendan chewableDogsCronus PharmaOral tabletN/AFDA-approved June 9, 2026

The GLP-1 developments aren’t happening in isolation. On June 9, 2026, Cronus Pharma’s pimobendan chewable tablets became available in the U.S. market as the first FDA-approved bioequivalent of Vetmedin for canine heart failure. That might sound unrelated, but it signals something real: the pipeline of condition-specific veterinary drugs is accelerating. Metabolic disease, cardiac disease, and chronic illness in pets are getting serious pharmaceutical attention in a way they weren’t five years ago.

The pet obesity crisis has been documented and discussed for two decades with limited results. A drug that removes the hunger equation without requiring perfect owner compliance could actually change outcomes. That’s not hype; that’s what the mechanism suggests if the safety profile continues to hold in larger trials.

We’re not there yet. But June 2026 is the closest we’ve ever been.

Sources

This article is for general informational purposes only and does not constitute veterinary advice. Pet health symptoms can have many causes and require professional evaluation. Always consult a licensed veterinarian for diagnosis and treatment specific to your pet.

Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.